Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTIQF3)

Drug Name
Treprostinil Drug Info
Synonyms
Treprostinilo; Treprostinilum; Uniprost; Viveta; Treprostinil sodium; LRX 15; U 62840; Remodulin (TN); Treprostinil [USAN:INN]; UT-15; Treprostinil (USAN/INN); U-62,840; ((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate; ({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid; 15 AU81; 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid; 2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
Therapeutic ClassAntihypertensive Agents
Cross-matching ID
PubChem CID
6918140
ChEBI ID
CHEMBL1237119
CAS Number
CAS 81846-19-7
TTD Drug ID
D01WUA
INTEDE Drug ID
DR1632

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Renin-angiotensin system 2.33 0.00e+0 20/23 (86.96%) MME;ANPEP;AGT;...
DNA replication 2.15 0.00e+0 34/36 (94.44%) RFC2;MCM2;MCM7;...
Steroid hormone biosynthesis -1.67 4.01e-2 43/61 (70.49%) HSD17B12;HSD3B2;CYP21A2;...
Propanoate metabolism -1.68 3.57e-2 30/34 (88.24%) HIBCH;BCKDHB;ALDH6A1;...
Type I diabetes mellitus -1.73 2.56e-2 38/43 (88.37%) CD86;HLA-B;HLA-F;...
Protein export -1.74 2.71e-2 17/23 (73.91%) SEC63;SPCS3;SRP14;...
Cell adhesion molecules -1.77 2.10e-2 118/148 (79.73%) CDH1;CLDN15;CNTNAP2;...
Biosynthesis of unsaturated fatty acids -1.78 2.34e-2 21/27 (77.78%) HSD17B12;TECR;HACD1;...
Autoimmune thyroid disease -1.81 2.30e-2 46/53 (86.79%) CD86;HLA-B;HLA-F;...
Graft-versus-host disease -1.83 1.88e-2 32/42 (76.19%) CD86;HLA-B;HLA-F;...
Asthma -1.88 1.17e-2 25/31 (80.65%) HLA-DOA;HLA-DOB;FCER1A;...
Allograft rejection -1.91 8.77e-3 32/38 (84.21%) CD86;HLA-B;HLA-F;...
Fatty acid elongation -1.98 2.19e-3 19/27 (70.37%) HADH;HSD17B12;TECR;...
Rheumatoid arthritis -2.00 2.92e-3 78/93 (83.87%) HLA-DRB1;IL18;VEGFA;...
Intestinal immune network for IgA production -2.00 4.38e-3 38/48 (79.17%) CD86;CCR10;CCR9;...
Valine, leucine and isoleucine degradation -2.05 8.77e-3 42/48 (87.5%) ACAA1;BCAT1;HIBCH;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Peripheral blood
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HL-60 CVCL_0002 Homo sapiens 0.37uM - 10uM 6H, 24H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.37uM - 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.37uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H